EARLY TAVR
2025
Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis
In 901 patients with asymptomatic severe aortic stenosis, early TAVR reduced death, stroke or unplanned cardiovascular hospitalisation compared with clinical surveillance.
Result
Efficacy: Death, stroke or unplanned CV hospitalisationHR 0.5
Below 1 favours early TAVR, above 1 favours clinical surveillance.
- Absolute difference
- 18.5 points
The absolute difference is derived from the event rates.
- Subtopic
- TAVR
- Design
- RCT, open-label
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2025 VHD
- Source
- Généreux P, et al. N Engl J Med. 2025;392(3):217-227.doi 10.1056/NEJMoa2405880
Discussion & critique
No mortality or stroke benefit: the composite is driven by 'soft' hospitalisations, with ~ 70 % crossover from surveillance. Contrasts with the neutral EVOLVED trial.